Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 

An image of vaccines.

ODA Rules Must Ensure that Vaccine Donations Count for the Poor

After buying up the World’s vaccine supply to ensure they can protect their own populations, rich countries have found themselves struggling to use the vaccine surpluses they accumulated. One response has been to donate the spare doses to countries who need them more. This is laudable, and countries who have done so want to receive credit for such actions in their aid statistics—what is known as Official Development Assistance (ODA).

We Should Track Global Vaccine Manufacturing Better - Here Is Why, and How

Poor understanding about vaccine capacity was one of the reasons why the world did not have the infrastructure needed to manufacture sufficient doses. This blogs proposes three actions to start tracking manufacturing capacity better and create robust estimates for the world’s vaccine manufacturing capacity.

Rail passengers wearing masks

It’s Freedom Day in the UK—but COVID Is Not Going Away Any Time Soon

The UK government is removing almost all COVID-19 restrictions from England in what the Prime Minister has as “Freedom Day”, but unfettered freedom does not exist. COVID is not going away any time soon. It’s time to prioritize transparency, consultation and long-term solutions. Everyone wants the world to return to normal, but we need to find a new normal that maximizes freedom in a world where COVID will be ever-present, rather than trying to return to a pre-pandemic status quo.

An image of shipping containers.

Shock to the System: Understanding Global Medical Supply, Shortages in COVID-19 Crisis, and How to Prepare for Future Disruptions

Since March of 2020, COVID-19 changed most aspects of life as we knew it, from our personal day-to-day activities to the systems, processes, and structures that keep the global economy interconnected and moving. This included pharmaceutical production and distribution, where anecdotal evidence suggested production problems, export bans, and trade disruption could significantly impact vital medicines access in low- and middle-income countries.

A figure of the summary of costs and consequences to consider in COVID-19 vaccine HTA.

Who Gets a COVID-19 Vaccine and Who Pays? The Need for Economic Analysis

In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.

Pages